P-284: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) — Kwee Yong (2022) | RDL Network
P-284: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Özgür Pektaş, Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, France Casca, Sandrine Macé, Marie‐Laure Risse, Thomas G. Martin
Thomas G. Martin, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau
Thomas G. Martin, Roman Hájek, Philippe Moreau, Bradley Augustson, Nelson Méndez, Tomáš Pika, Sosana Delimpasi, Javier de la Rubia, Ângelo Maiolino, Tony Reiman, Joaquín Martínez‐López, Joseph Mıkhael, Kwee Yong, Marie‐Laure Risse, France Casca, Sylvia Marion, Sandrine Macé, Meletios A Dimopoulos
Thomas G. Martin, Roman Hájek, Philippe Moreau, Bradley Augustson, Nelson Méndez, Tomáš Pika, Sosana Delimpasi, Javier de la Rubia, Ângelo Maiolino, Tony Reiman, Joaquín Martínez‐López, Joseph Mıkhael, Kwee Yong, Marie‐Laure Risse, France Casca, Sylvia Marion, Sandrine Macé, Meletios A Dimopoulos
Roman Hájek, Philippe Moreau, Bradley Augustson, Nelson Méndez, Tomáš Pika, Sosana Delimpasi, Javier de la Rubia, Ângelo Maiolino, Tony Reiman, Joaquín Martínez‐López, T. John Martin, Joseph Mıkhael, Kwee Yong, Marie‐Laure Risse, France Casca, Sylvia Marion, Sandrine Macé, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.